Dwight D. Koeberl

6.2k citations

130 papers · 4.3k indexed · 1 hit paper · h-index 36

Physiology top 1%
Molecular Biology top 5%
Genetics top 1%
Rheumatology top 0.5%
Epidemiology top 5%

Co-authors: Priya S. Kishnani Baodong Sun Sarah P. Young Andrew Bird Deeksha Bali Songtao Li Haoyue Zhang T. T. Brown
Topics: Lysosomal Storage Disorders Research (54 papers)Glycogen Storage Diseases and Myoclonus (52 papers)Genetics and Neurodevelopmental Disorders (26 papers)
Cited by: Rheumatology Clinical Biochemistry Physiology
Journals: Nature Proceedings of the National Academy of Sciences Nucleic Acids Research
Partner nations: United States United Kingdom Taiwan

In The Last Decade

Dwight D. Koeberl

128 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia

2024 55 citations Dwight D. Koeberl, Andreas Schulze et al. Nature profile →

Peers

Countries citing papers authored by Dwight D. Koeberl

Since Specialization

Citations

This map shows the geographic impact of Dwight D. Koeberl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dwight D. Koeberl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dwight D. Koeberl more than expected).

Fields of papers citing papers by Dwight D. Koeberl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dwight D. Koeberl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dwight D. Koeberl. The network helps show where Dwight D. Koeberl may publish in the future.

Co-authorship network of co-authors of Dwight D. Koeberl

This figure shows the co-authorship network connecting the top 25 collaborators of Dwight D. Koeberl. A scholar is included among the top collaborators of Dwight D. Koeberl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dwight D. Koeberl. Dwight D. Koeberl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacious genome editing in infant mice with glycogen storage disease type Ia 2025 ·JCI Insight ·(unknown),(unknown),Thomas W. Beck,Songtao Li,Elizabeth D. Brooks,(unknown),(unknown),(unknown),Sarah Chan,(unknown),David Courtney,Jeffrey I. Everitt,Bryan R. Cullen,Dwight D. Koeberl	0
2	The attenuated hepatic clearance of propionate increases cardiac oxidative stress in propionic acidemia 2024 ·Basic Research in Cardiology ·(unknown),(unknown),(unknown),(unknown),Eva Richard,Lourdes R. Desviat,Sarah P. Young,Dwight D. Koeberl,Takhar Kasumov,Xiaoxin Chen,Guofang Zhang	3
3	A case study of inclusion of rural populations in research: Implications for science and health equity 2024 ·Clinical and Translational Science ·Devon Noonan,Wendy K. K. Lam,James Goodrich,(unknown),Keisha L. Bentley‐Edwards,Dwight D. Koeberl,(unknown),F. Joseph McClernon	2
4	Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemiabreakdown → 2024 ·Nature ·Dwight D. Koeberl,Andreas Schulze,Neal Sondheimer,Gerald S. Lipshutz,Tarekegn Geberhiwot,Lerong Li,Rajnish Saini,Junxiang Luo,Vanja Sikirica,Ling Jin,M. Liang,(unknown),Stephanie Grünewald	55
5	Clinical, biochemical and molecular characterization of 12 patients with pyruvate carboxylase deficiency treated with triheptanoin 2023 ·Molecular Genetics and Metabolism ·(unknown),(unknown),(unknown),Leigh Anne Flore,April Rasala Lehman,Natasha Shur,Parul Jayakar,Bryan E. Hainline,Alice Basinger,William G. Wilson,George A. Díaz,Richard W. Erbe,Dwight D. Koeberl,Jerry Vockley,Jirair K. Bedoyan	2
6	Phase I study of liver depot gene therapy in late-onset Pompe disease 2023 ·Molecular Therapy ·Edward C. Smith,Sam Hopkins,Laura E. Case,Ming Xu,(unknown),Stephanie DeArmey,Sang-oh Han,(unknown),Jessica A. Chichester,Edward H. Bossen,Christoph P. Hornik,Jennifer L. Cohen,Deeksha Bali,Priya S. Kishnani,Dwight D. Koeberl	24
7	Moving away from one disease at a time: Screening, trial design, and regulatory implications of novel platform technologies 2023 ·American Journal of Medical Genetics Part C Seminars in Medical Genetics ·(unknown),Philip J. Brooks,Dwight D. Koeberl,Amy Brower,Aaron J. Goldenberg,Robert C. Green,Jill A. Morris,Joseph J. Orsini,Timothy W. Yu,Erika F. Augustine	5
8	Successful AAV8 readministration: Suppression of capsid‐specific neutralizing antibodies by a combination treatment of bortezomib and CD20 mAb in a mouse model of Pompe disease 2023 ·The Journal of Gene Medicine ·Su Jin Choi,John S. Yi,Jeong‐A Lim,Thomas F. Tedder,Dwight D. Koeberl,William R. Jeck,Ankit K. Desai,Amy S. Rosenberg,Baodong Sun,Priya S. Kishnani	11
9	Screening data from 19 patients with late‐onset Pompe disease for a phase I clinical trial of AAV8 vector‐mediated gene therapy 2023 ·JIMD Reports ·(unknown),Laura E. Case,Edward C. Smith,(unknown),Deeksha Bali,Priya S. Kishnani,Dwight D. Koeberl	1
10	Expanding allelic and phenotypic spectrum of ZC4H2‐related disorder: A novel hypomorphic variant and high prevalence of tethered cord 2022 ·Clinical Genetics ·Parith Wongkittichote,Tae‐Ik Choi,(unknown),(unknown),Dwight D. Koeberl,Vinodh Narayanan,Keri Ramsey,Chris Balak,Charles E. Schwartz,Anna M. Cueto‐González,Francina Munell,Cheol‐Hee Kim,Marwan Shinawi	5
11	Minimum Effective Dose to Achieve Biochemical Correction with Adeno-Associated Virus Vector-Mediated Gene Therapy in Mice with Pompe Disease 2022 ·Human Gene Therapy ·Sang-oh Han,(unknown),Songtao Li,(unknown),Dwight D. Koeberl	10
12	Efficacious Androgen Hormone Administration in Combination with Adeno-Associated Virus Vector-Mediated Gene Therapy in Female Mice with Pompe Disease 2022 ·Human Gene Therapy ·Sang-oh Han,(unknown),Alex L. Chang,(unknown),Songtao Li,Elizabeth D. Brooks,Dwight D. Koeberl	3
13	Three-dimensional tissue-engineered human skeletal muscle model of Pompe disease 2021 ·Communications Biology ·Jason Wang,(unknown),Alastair Khodabukus,(unknown),Sang-oh Han,Aaron L. Carlson,Lauran Madden,Priya S. Kishnani,Dwight D. Koeberl,Nenad Bursac	26
14	A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia 2019 ·Thyroid ·Jin Zhou,(unknown),Andrea Lim,Xiao-Hui Liao,(unknown),Hiroko Masamune,Samuel Refetoff,(unknown),Dwight D. Koeberl,Paul M. Yen	51
15	Pathogenesis of Hepatic Tumors following Gene Therapy in Murine and Canine Models of Glycogen Storage Disease 2019 ·Molecular Therapy — Methods & Clinical Development ·(unknown),Monika Gjorgjieva,Stephanie Smith,Elizabeth D. Brooks,Zelin Chen,Shawn M. Burgess,Randy J. Chandler,(unknown),(unknown),Songtao Li,Gilles Mithieux,Charles P. Venditti,Fabienne Rajas,Dwight D. Koeberl	13
16	Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β ₂ -Agonist in Murine Pompe Disease 2015 ·Human Gene Therapy ·Sang-oh Han,Songtao Li,Andrew Bird,Dwight D. Koeberl	15
17	β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease 2011 ·Molecular Genetics and Metabolism ·Dwight D. Koeberl,Songtao Li,Jian Dai,Beth L. Thurberg,Deeksha Bali,Priya S. Kishnani	40
18	Efficacy of an Adeno-associated Virus 8-Pseudotyped Vector in Glycogen Storage Disease Type II 2004 ·Molecular Therapy ·Baodong Sun,Haoyue Zhang,Luis M. Franco,Sarah P. Young,Ayn Schneider,Andrew Bird,Andrea Amalfitano,Y.-T. Chen,Dwight D. Koeberl	112
19	Reply to Hsu. 1996 ·The American Journal of Human Genetics ·Virginia P. Sybert,Dwight D. Koeberl,Barbara McGillivray	1
20	Comparison of direct and indirect methods of carrier detection in an X‐linked disease 1990 ·American Journal of Medical Genetics ·Dwight D. Koeberl,C. D. K. Bottema,Steve S. Sommer	5

About Dwight D. Koeberl

Dwight D. Koeberl is a scholar working on Rheumatology, Clinical Biochemistry and Physiology, having authored 130 papers that have together received 4.3k indexed citations. Recurring topics across this work include Lysosomal Storage Disorders Research (54 papers), Glycogen Storage Diseases and Myoclonus (52 papers) and Genetics and Neurodevelopmental Disorders (26 papers). The work is most often cited by research in Rheumatology (1.5k citations), Clinical Biochemistry (611 citations) and Physiology (1.8k citations). Dwight D. Koeberl has collaborated with scholars based in United States, United Kingdom and Taiwan. Frequent co-authors include Priya S. Kishnani, Baodong Sun, Sarah P. Young, Andrew Bird, Deeksha Bali, Songtao Li, Haoyue Zhang, T. T. Brown, A. Dusty Miller and Christine L. Halbert. Their work appears in journals such as Nature, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact